<DOC>
	<DOCNO>NCT02601287</DOCNO>
	<brief_summary>This safety efficacy study BOTOX® ( Botulinum Toxin Type A ) Treatment Adult Korean Patients Urinary Incontinence due Neurogenic Detrusor Overactivity Overactive Bladder .</brief_summary>
	<brief_title>A Safety Efficacy Study Botulinum Toxin Type A ( BOTOX® ) Treat Urinary Incontinence Due Neurogenic Detrusor Overactivity Overactive Bladder Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Urinary incontinence result neurogenic overactive bladder due spinal cord injury multiple sclerosis Symptoms urge urinary incontinence , urgency , frequency due overactive bladder Myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis Use botulinum toxin therapy serotype 3 month prior screen Has acute urinary retention routinely perform clean intermittent selfcatheterization ( CIC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>